Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Accurate Tool Developed to Track New HIV Infections

By LabMedica International staff writers
Posted on 04 Jan 2018
Print article
Image: The Bio-Plex 200 is a suspension multiplexing array fluorescence reader used for multiplex assays that allows to measure up to 100 biomolecule of protein or nucleic acid in a single sample (Photo courtesy of Bio-Rad Laboratories).
Image: The Bio-Plex 200 is a suspension multiplexing array fluorescence reader used for multiplex assays that allows to measure up to 100 biomolecule of protein or nucleic acid in a single sample (Photo courtesy of Bio-Rad Laboratories).
An effort is underway to develop a more accurate way to gauge the incidence of human immunodeficiency virus (HIV) infections in large populations, which will improve scientific studies and prevention strategies worldwide.

Accurate HIV-1 incidence estimation is critical to the success of HIV-1 prevention strategies. Current assays are limited by high false recent rates (FRRs) in certain populations and a short mean duration of recent infection (MDRI).

A large team of scientists working with those at Duke University Medical Center (Durham, NC, USA) received for testing 132 well-characterized untreated specimens drawn within 800 days of estimated date of seroconversion (EDSC) (120 unique subjects) for MDRI estimation and 134 specimens (121 subjects) from untreated and 58 specimens (56 subjects) from treated longstanding infection for FRR estimation. Specimens were largely from subjects infected with subtypes B (56%) and C (43%).

The investigators profiled HIV-1–specific binding antibody responses in participant serum or plasma. They evaluated antibody binding to a unique and broad set of HIV-1 antigens that included gp120, gp140, and V1-V2 antigens of multiple subtypes (i.e., A, CRF01-AE, B, C, and CRF07-BC) from both sexes. Serum and plasma were diluted in binding antibody multiplex assays (BAMA) and detection performed on either a Bioplex 200 or Luminex FM3D machine.

The scientists found that discriminant function analysis identified an optimal set of measurements that were subsequently evaluated in a 324-specimen blinded biomarker validation panel. These biomarkers included clade C gp140 IgG3, transmitted/founder clade C gp140 IgG4 avidity, clade B gp140 IgG4 avidity, and gp41 immunodominant region IgG avidity. MDRI was estimated at 215 day or alternatively, 267 days. FRRs in untreated and treated subjects were 5.0% and 3.6%, respectively.

Georgia Tomaras, PhD, a professor in the Department of Surgery and senior author of the study, said, “Recent advances, including effective anti-retroviral drugs that both treat and prevent HIV infections, have changed the landscape in the HIV field. Improved methods for classifying recent infection from older infections are critically needed to help identify the most effective prevention strategies. Having a more accurate HIV incidence test could substantially reduce costs for scientists, because they would need a much smaller sample size to enroll in studies.” The study was published on December 21, 2017, in the journal JCI Insight.

Related Links:
Duke University Medical Center

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.